Trial Profile
A phase Ib, multicentre, randomized, double-blind, cohort, placebo-controlled, multiple ascending-dose study to evaluate the safety, tolerability and pharmacokinetics of PSI 938 (GS-0938), Sofosbuvir (GS-7977, PSI 7977) and their combination in treatment-naive patients with chronic hepatitis C genotype 1 infection.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Dec 2015
Price :
$35
*
At a glance
- Drugs PSI 938 (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Acronyms NUCLEAR
- 28 Mar 2011 Results will be presented at EASL-2011 according to a Pharmasset media release.
- 06 Jan 2011 Interim results for the PSI 938 300mg QD group presented in a Pharmasset media release
- 06 Jan 2011 Patients now being enrolled in the second and third cohorts, and further data expected to be reported during the first quarter of 2011, according to a Pharmasset media release